aTyr Pharma, Inc.(ATYR)

$0.50—

Chart

aTyr Pharma, Inc.(ATYR)

NASDAQ

$0.50—

Chart Studio

ATYR(ATYR)

ATYR

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.11

Nov 5, 2026

Revenue Estimate

$3M

FY2030E EPS$0.29

Analyst Sentiment

Wall St. Consensus

Hold

9 analysts·Limited coverage

Score

3 Buy (33%)6 Hold (67%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

333%

Hold

667%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$1.00

+99.4%

Consensus

$1.25

+149.3%

Bull

$17.00

+3289.8%

12-Month Target Range9 analysts

$1.00$1.25$17.00

Current $0.50Consensus

Current Price

$0.50

Upside to Consensus

$0.75

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+127.95%

EPS—

FY2028

Rev-56.00%

EPS—

FY2029

Rev+2008.44%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$4M	$9M	$4M	$82M	$179M
Low	$4M	$9M	$4M	$82M	$179M
High	$4M	$9M	$4M	$82M	$179M
EBITDA Avg	$-2M	$-5M	$-2M	$-49M	$-107M
Low	$-2M	$-5M	$-2M	$-49M	$-107M
High	$-2M	$-5M	$-2M	$-49M	$-107M
EBIT Avg	$-2M	$-5M	$-2M	$-49M	$-107M
Low	$-2M	$-5M	$-2M	$-49M	$-107M
High	$-2M	$-5M	$-2M	$-49M	$-107M
Net Income Avg	$-41M	$-50M	$-36M	$-23M	$27M
Low	$-47M	$-53M	$-55M	$-23M	$27M
High	$-37M	$-30M	$-18M	$-23M	$27M
EPS Avg	$-0.46	$-0.44	$-0.37	$-0.24	$0.29
Low	$-0.51	$-0.57	$-0.59	$-0.24	$0.29
High	$-0.39	$-0.32	$-0.19	$-0.24	$0.29
Analysts (Rev / EPS)	6 / 6	6 / 6	7 / 7	3 / 2	5 / 4

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$3M	$10M	—	$8M	$19M	$44M
Low	$3M	$10M	—	$8M	$19M	$44M
High	$3M	$10M	—	$8M	$19M	$44M
EBITDA Avg	$-2M	$-6M	—	$-5M	$-11M	$-26M
Low	$-2M	$-6M	—	$-5M	$-11M	$-26M
High	$-2M	$-6M	—	$-5M	$-11M	$-26M
EBIT Avg	$-2M	$-6M	—	$-5M	$-11M	$-26M
Low	$-2M	$-6M	—	$-5M	$-11M	$-26M
High	$-2M	$-6M	—	$-5M	$-11M	$-26M
Net Income Avg	$-10M	$-9M	$-10M	$-9M	$-9M	$-9M
Low	$-11M	$-12M	$-10M	$-9M	$-9M	$-9M
High	$-9M	$-5M	$-10M	$-9M	$-9M	$-9M
EPS Avg	$-0.10	$-0.09	$-0.10	$-0.09	$-0.10	$-0.09
Low	$-0.11	$-0.13	$-0.10	$-0.09	$-0.10	$-0.09
High	$-0.09	$-0.06	$-0.10	$-0.09	$-0.10	$-0.09
Analysts (Rev / EPS)	9 / 4	9 / 4	— / 1	9 / 1	9 / 1	9 / 1

Earnings Surprises

Recent Analyst Actions

Sep 15, 2025RBC Capital

aTyr Pharma downgraded to Sector Perform from Outperform at RBC Capital

Target:$1.50

+47.8%from $1.01

Sep 15, 2025Wells Fargo

aTyr Pharma downgraded to Equal Weight from Overweight at Wells Fargo

Target:$1.00

-1.5%from $1.01

Sep 15, 2025Leerink Partners

aTyr Pharma downgraded to Market Perform from Outperform at Leerink

Target:$1.00

-1.5%from $1.01

Aug 22, 2025Jefferies

aTyr Pharma price target raised to $17 from $9 at Jefferies

Target:$17.00

+217.8%from $5.35

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance